García J R, Cozar M, Soler M, Bassa P, Riera E, Ferrer J
Unidad PET/TC, CETIR, ERESA, Esplugues, Barcelona, España.
Unidad PET/TC, CETIR, ERESA, Esplugues, Barcelona, España.
Rev Esp Med Nucl Imagen Mol. 2016 Jul-Aug;35(4):238-45. doi: 10.1016/j.remn.2015.11.007. Epub 2016 Jan 21.
To assess the prognostic value of the therapeutic response by (11)C-choline PET/CT in prostate cancer patients with biochemical recurrence in which (11)C-choline PET/CT indicated radio-guided radiotherapy.
The study included 37 patients initially treated with prostatectomy, who were treated due to biochemical recurrence. (11)C-choline PE/CT detected infra-diaphragmatic lymph-node involvement. All were selected for intensity modulated radiation therapy, escalating the dose according to the PET findings. One year after treatment patients underwent PSA and (11)C-choline PET/CT categorizing response (complete/partial/progression). Clinical/biochemical/image monitoring was performed until appearance of second relapse or 36 months in disease-free patients.
(11)C-choline PET/CT could detect lymph nodes in all 37 patients. They were 18 (48.6%) of more than a centimetre in size and 19 (51.3%) with no pathological CT morphology: 9 (24.3%) with positive lymph nodes of around one centimetre and 10 (27.0%) only less than a centimetre in size. The response by (11)C-choline PET/CT was categorised one year after radiotherapy: 16 patients (43.2%) complete response; 15 (40.5%) partial response, and 6 (16.2%) progression. The response was concordant between the PSA result and (11)C-choline PET/CT in 32 patients (86.5%), and discordant in five (13.5%). New recurrence was detected in 12 patients (80%) with partial response, and 5 (31.2%) with complete response. The mean time to recurrence was 9 months after partial response, and 18 months after complete response (significant difference, p<.0001).
(11)C-choline PET/CT allows the selection of patients with recurrent prostate cancer candidates for radiotherapy and to plan the technique. The evaluation of therapeutic response by (11)C-choline PET/CT has prognostic significance.
评估¹¹C - 胆碱PET/CT对生化复发前列腺癌患者的治疗反应的预后价值,这些患者的¹¹C - 胆碱PET/CT显示可进行放射性引导放疗。
该研究纳入了37例最初接受前列腺切除术且因生化复发而接受治疗的患者。¹¹C - 胆碱PET/CT检测到膈下淋巴结受累。所有患者均选择调强放射治疗,并根据PET结果增加剂量。治疗一年后,患者接受PSA和¹¹C - 胆碱PET/CT检查以分类反应(完全缓解/部分缓解/进展)。进行临床/生化/影像监测直至第二次复发出现或无病患者达到36个月。
¹¹C - 胆碱PET/CT可检测到所有37例患者的淋巴结。其中,大小超过1厘米的有18例(48.6%),无病理性CT形态的有19例(51.3%):9例(24.3%)淋巴结阳性且大小约1厘米,10例(27.0%)仅小于1厘米。放疗一年后,¹¹C - 胆碱PET/CT的反应分类为:16例患者(43.2%)完全缓解;15例(40.5%)部分缓解,6例(16.2%)进展。32例患者(86.5%)的PSA结果与¹¹C - 胆碱PET/CT反应一致,5例(13.5%)不一致。部分缓解的12例患者(80%)和完全缓解的5例患者(31.2%)检测到新的复发。部分缓解后复发的平均时间为9个月,完全缓解后为18个月(差异有统计学意义,p<0.0001)。
¹¹C - 胆碱PET/CT有助于选择适合放疗的复发性前列腺癌患者并规划放疗技术。¹¹C - 胆碱PET/CT对治疗反应的评估具有预后意义。